My Cart

Rat ADAM9 Protein, His Tag, low endotoxin (active enzyme, MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
AD9-R52H4-50ug
$465.00
AD9-R52H4-500ug
$1750.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Synonyms

    Disintegrin and metalloproteinase domain-containing protein 9 (EC:3.4.24.-) Cellular disintegrin-related protein, Meltrin-gamma, Metalloprotease, disintegrin, cysteine-rich protein 9, Myeloma cell metalloproteinase, ADAM9, KIAA0021, MCMP, MDC9, MLTNG

  • Source

    Rat ADAM9 Protein, His Tag (AD9-R52H4) is expressed from human 293 cells (HEK293). It contains AA Ala 206 - Asp 697 (Accession # Q58GH6).

    Request for sequence
  • Molecular Characterization

    ADAM9 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 55.2 kDa. The protein migrates as 60-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Supplied as 0.2 μm filtered solution in 20 mM Tris, 500 mM NaCl, pH7.3 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    ADAM9 SDS-PAGE

    Rat ADAM9 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    ADAM9 SEC-MALS

    The purity of Rat ADAM9 Protein, His Tag (Cat. No. AD9-R52H4) is more than 90% and the molecular weight of this protein is around 50-75 kDa verified by SEC-MALS.

    Report
  • Bioactivity-SPR

     ADAM9 SPR

    Anti-ADAM9 Antibody captured on Protein A Chip can bind Rat ADAM9 Protein, His Tag (Cat. No. AD9-R52H4) with an affinity constant of 21.6 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity

    Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2. The specific activity is >70 pmol/min/µg (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases.Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumoraggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers.Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.

Recent Advances

 
Drug Development Progress
  • English Name:

    Disintegrin and metalloproteinase domain-containing protein 9

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    3 Details

  • Highest Development Stage:

    Phase 2 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland